<DOC>
	<DOCNO>NCT01072331</DOCNO>
	<brief_summary>The purpose study evaluate effect MP-513 24-h glycemic control patient type 2 Diabetes 4 week administration .</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic Study MP-513 With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients 20 75 year old Patients dietary management take therapeutic exercise diabetes 8 week administration investigational drug Patients whose HbA1c â‰¥6.5 % &lt; 10.0 % Patients administer diabetes therapeutic drug prohibit concomitant use within 8 week administration investigational drug . Patients type 1 diabetes , diabetes mellitus cause pancreas impairment , secondary diabetes ( Cushing disease , acromegaly , etc ) Patients accept treatment arrhythmias Patients serious diabetic complication Patients excessive alcohol addict Patients severe hepatic disorder severe renal disorder . Patients pregnant , lactating , probably pregnant patient , patient agree contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>